Company
Radiopharmaceutical Specialists
CPDC was founded by Dr. John Valliant of McMaster University in 2008 as a Centre of Excellence for Commercialization and Research (CECR), specializing in radiopharmaceutical research and development. CPDC’s mission is to improve the quality of Canadian patients’ lives through the commercialization of advanced research and the clinical development of nuclear medicine.
CPDC has been integral
to the growth of the radiopharmaceutical ecosystem in Canada.
CPDC has brought over a dozen radiopharmaceuticals into clinical development, which currently supports more than 25 clinical trials in Canada, North America and Europe.
CPDC has successfully incubated, grown, and spun-out two Canadian-based radiopharmaceutical companies: Fusion Pharmaceuticals Inc., and AtomVie Global Radiopharma.
CPDC and its partners have provided more than 65,000 clinical doses to patients in Canada for a variety of diseases.
